Molecular dynamics reveal that isoDGR-containing cyclopeptides are true αvβ3 antagonists unable to promote integrin allostery and activation.

Ain't got that swing(-out): The cyclopeptide isoDGR is emerging as a new αvβ3 integrin binding motif. Agreement between the results of computational and biochemical studies reveals that isoDGR-containing cyclopeptides are true αvβ3 integrin antagonists that block αvβ3 in its inactive conformation (see scheme). isoDGR-based ligands may give αvβ3 antagonists without paradoxical effects.

[1]  H. Kessler,et al.  Konformative Kontrolle über Integrin-Subtyp-Selektivitäten in isoDGR-Peptidmotiven: ein biologischer Schalter† , 2010 .

[2]  S. Honda,et al.  Topography of Ligand-induced Binding Sites, Including a Novel Cation-sensitive Epitope (AP5) at the Amino Terminus, of the Human Integrin Subunit (*) , 1995, The Journal of Biological Chemistry.

[3]  M. Humphries,et al.  Linking integrin conformation to function , 2009, Journal of Cell Science.

[4]  H. Kessler,et al.  Strukturen von Integrinen und ihren Ligandkomplexen – Implikationen für das Medikamenten‐Design und die Signaltransduktion , 2002 .

[5]  A. Spitaleri,et al.  2D TR-NOESY experiments interrogate and rank ligand-receptor interactions in living human cancer cells. , 2010, Angewandte Chemie.

[6]  E. Novellino,et al.  Conformational control of integrin-subtype selectivity in isoDGR peptide motifs: a biological switch. , 2010, Angewandte Chemie.

[7]  K. Peter,et al.  Therapeutic integrin inhibition: Allosteric and activation-specific inhibition strategies may surpass the initial ligand-mimetic strategies , 2008, Thrombosis and Haemostasis.

[8]  Viola Vogel,et al.  Integrin Activation Dynamics between the RGD-binding Site and the Headpiece Hinge* , 2009, The Journal of Biological Chemistry.

[9]  Horst Kessler,et al.  The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction. , 2002, Angewandte Chemie.

[10]  S. Robinson,et al.  The role of β3-integrins in tumor angiogenesis: context is everything. , 2011, Current opinion in cell biology.

[11]  Barry S. Coller,et al.  Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics , 2004, Nature.

[12]  T. Walz,et al.  Intact αIIbβ3 Integrin Is Extended after Activation as Measured by Solution X-ray Scattering and Electron Microscopy* , 2011, The Journal of Biological Chemistry.

[13]  Klaus Schulten,et al.  How the headpiece hinge angle is opened: new insights into the dynamics of integrin activation , 2006, The Journal of cell biology.

[14]  A. Spitaleri,et al.  Use of metadynamics in the design of isoDGR-based αvβ3 antagonists to fine-tune the conformational ensemble. , 2011, Angewandte Chemie.

[15]  T. Springer,et al.  Closed headpiece of integrin αIIbβ3 and its complex with an αIIbβ3-specific antagonist that does not induce opening. , 2010, Blood.

[16]  J. Norman,et al.  Integrins: masters and slaves of endocytic transport , 2009, Nature Reviews Molecular Cell Biology.

[17]  Marian Brennan,et al.  Integrins as therapeutic targets: lessons and opportunities , 2010, Nature Reviews Drug Discovery.

[18]  Timothy A. Springer,et al.  Therapeutic antagonists and conformational regulation of integrin function , 2003, Nature Reviews Drug Discovery.

[19]  J Andrew McCammon,et al.  Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations. , 2009, Journal of molecular biology.

[20]  M. Schwartz,et al.  Rac recruits high-affinity integrin αvβ3 to lamellipodia in endothelial cell migration , 2001, Nature Cell Biology.

[21]  R. Longhi,et al.  Structural Basis for the Interaction of isoDGR with the RGD-binding Site of αvβ3 Integrin* , 2008, Journal of Biological Chemistry.

[22]  R. Longhi,et al.  Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif. , 2008, Cancer research.

[23]  Davide Provasi,et al.  Targeted molecular dynamics reveals overall common conformational changes upon hybrid domain swing‐out in β3 integrins , 2009, Proteins.

[24]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[25]  H. Berendsen,et al.  Essential dynamics of proteins , 1993, Proteins.

[26]  G. Alghisi,et al.  The Integrin Antagonist Cilengitide Activates αVβ3, Disrupts VE-Cadherin Localization at Cell Junctions and Enhances Permeability in Endothelial Cells , 2009, PLoS ONE.